

Pr. Yves LEVY (Chairman of Aviesan) – Dr. Claude BERTRAND (Chairman of ARIIS)

- 08:15**      **W**elcome coffee
- 09:00**      **O**pening remarks  
*Dr. Claude BERTRAND, Chairman of ARIIS*
- 09:10**      **F**rench Ministry of Research and Higher Education: strategic update  
*Mr. Roger GENET, Directeur Général Recherche et Innovation, MENESR*
- 09:30**      **A**viesan: a new landscape for Epidemiology and Cohorts in France  
*Pr. Geneviève CHÊNE, Directeur ITMO Santé Publique - Aviesan*
- 09:50**      **C**ohorts: industry expectations  
*Dr. Susan SHIFF, Senior Vice President, Center of Observational and Real-World Evidence, MSD (Merck & Co., Inc., USA)*
- 10:10**      **C**ohorts: the European perspective  
*Pr. Nancy PEDERSEN, Dept. Of Medical Epidemiology and Biostatistics, Karolinska Institutet, Head of the LifeGene Cohort*
- 10:30**      **C**offee Break
- 11:00**      **R**ound table 1- Cohorts in France: a favorable ecosystem (Moderator A-F Berthon)  
  - *Mr Jean-Christophe DANTONEL, CGI*
  - *Ms Gaëlle NACHBAUR, GSK*
  - *Mr Claude GISSOT, CNAM-TS*
  - *Mr Xavier REY-COQUAIS, ACTIF santé*
  - *Ms Frédérique LESAULNIER, ITMO Santé Publique*
- 12:00**      **R**ound table 2 – Maximizing the value of cohorts (Moderator A-F Berthon)  
  - *Pr. Jill PELL UK, Biobank*
  - *Dr. Hermann NABI, Institut national du cancer*
  - *Dr. Guy FAGHERAZZI, Inserm*
  - *Dr. Marisol URBIETA, Roche*
  - *Pr. Archana SINGH-MANOUX, Inserm – University College of London*
- 1:00pm**      **C**oncluding remarks  
*Dr. Claude BERTRAND, Chairman of ARIIS*
- 1:10pm**      **L**unch
- 2:00pm**      **B2B** Meetings